Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Staskin

Showing results (1-10 of 54) with videos related to

Pageof 6
Sort By:
Expert Opinion on Pharmacotherapy|September 1, 2022
Clinical direction in the pharmacological and device management of refractory overactive bladder: the urge to develop new treatmentsDavid Staskin
Therapeutic Advances in Urology|January 27, 2022
Comment on: update on the management of overactive bladderDavid Staskin
The Urologic Clinics of North America|December 13, 2002
Genuine stress incontinence theories of etiology and surgical correctionLouis Plzak, David Staskin
Current Opinion in Urology|October 6, 2005
Mixed incontinence: definitions, outcomes, and interventionsRoger Dmochowski, David Staskin
Neurourology and Urodynamics|May 1, 2010
Female pelvic surgical devices and techniques need better evidence-based medicineDavid Staskin, Vik Khullar
The Journal of Urology|May 1, 2023
Effect of Pharmacotherapy for Overactive Bladder on the Incidence of and Factors Related to Urinary Tract Infection: A Systematic Review and Meta-analysis. LetterAhmet Urkmez, David Staskin
Urology|December 21, 2002
Overactive bladder in men: special considerations for evaluation and managementRoger R Dmochowski, David Staskin
Biomedicines|February 25, 2022
Study Designs for Evaluation of Combination Treatment: Focus on Individual Patient BenefitMartin C Michel, David Staskin
Expert Opinion on Pharmacotherapy|April 6, 2002
Oxybutynin chloride: alterations in drug delivery and improved therapeutic indexRoger Dmochowski, Sherron Kell, David Staskin
Urology|January 31, 2024
Oxybutynin-associated Cognitive Impairment: Evidence and Implications for Overactive Bladder TreatmentMichael B Chancellor, Alvaro Lucioni, David Staskin
Pageof 6

Showing results (1-10 of 54) with videos related to

Sort By:
Pageof 6
Expert Opinion on Pharmacotherapy|September 1, 2022
Clinical direction in the pharmacological and device management of refractory overactive bladder: the urge to develop new treatmentsDavid Staskin
Therapeutic Advances in Urology|January 27, 2022
Comment on: update on the management of overactive bladderDavid Staskin
The Urologic Clinics of North America|December 13, 2002
Genuine stress incontinence theories of etiology and surgical correctionLouis Plzak, David Staskin
Current Opinion in Urology|October 6, 2005
Mixed incontinence: definitions, outcomes, and interventionsRoger Dmochowski, David Staskin
Neurourology and Urodynamics|May 1, 2010
Female pelvic surgical devices and techniques need better evidence-based medicineDavid Staskin, Vik Khullar
The Journal of Urology|May 1, 2023
Effect of Pharmacotherapy for Overactive Bladder on the Incidence of and Factors Related to Urinary Tract Infection: A Systematic Review and Meta-analysis. LetterAhmet Urkmez, David Staskin
Urology|December 21, 2002
Overactive bladder in men: special considerations for evaluation and managementRoger R Dmochowski, David Staskin
Biomedicines|February 25, 2022
Study Designs for Evaluation of Combination Treatment: Focus on Individual Patient BenefitMartin C Michel, David Staskin
Expert Opinion on Pharmacotherapy|April 6, 2002
Oxybutynin chloride: alterations in drug delivery and improved therapeutic indexRoger Dmochowski, Sherron Kell, David Staskin
Urology|January 31, 2024
Oxybutynin-associated Cognitive Impairment: Evidence and Implications for Overactive Bladder TreatmentMichael B Chancellor, Alvaro Lucioni, David Staskin
Pageof 6